Chipscreen Biosciences, a leading integrated Chinese biotech company specialized in discovery and development of novel small molecule pharmaceuticals with a primary focus in oncology, metabolic disease, and autoimmune diseases, announce the signing of a collaboration agreement with Innovent Biologics, Inc. (Innovent) to evaluate the safety and tolerability of Chipscreen's Chidamide and Innovent's Sintilimab in combination with an anti-VEGF monoclonal antibody IBI305 in patients with advanced colorectal carcinoma.
The global interferons market is expected to post a CAGR of close to 2% during the period 2019-2023, according to the latest market research report by Technavio.
“A separate coding and payment policy for biosimilars could offer greater savings to the Medicare program, as well as encourage greater price competition and uptake of biosimilar products in the marketplace. Ultimately, patients would benefit the most from a payment policy that enhances access, achieves long-term savings, and supports a competitive marketplace.”
AffaMed Therapeutics, a new biopharmaceutical company founded and funded by C-Bridge Capital, a healthcare private equity firm focused on the development and late-stage investment opportunities, announced today that it is partnering with Samsung Bioepis to accelerate the commercialization of multiple next-generation biosimilars in China. Pharmaceutical industry veteran, Dr. Nathan Pang, will lead the Company as CEO.
Samsung Bioepis Co., Ltd. recently announced its expansion in mainland China through a licensing agreement with C-Bridge Capital.
The Mundipharma network of independent associated companies recently announced the launch of Pelmeg (pegfilgrastim), a biosimilar of Neulasta following European Commission (EC) approval in November 2018.
Paras Biopharmaceuticals Finland Oy recently announced the achievement of a major milestone – the successful development of biologically active Romiplostim (N-Plate biosimilar) production technology.
Fresenius Kabi announced recently that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion, recommending marketing authorization for MSB11022, a biosimilar candidate of Humira (adalimumab).
Beyond K-pop and K-food, K-biologics is set to increase in popularity. According to Reports, Korea’s “bio fever” is being spurred on by the domestic development of biosimilars by firms such as Celltrion, Samsung Bioepis, LG Chem, GC Green Cross, Chong Kun Dang, CJ Healthcare, and Dong-A ST.
The Biosimilars Forum applauded today’s proposed HHS rule attacking negotiated rebates between manufacturers and insurers.
|
|
|
|
|
|
|
|
|